Last reviewed · How we verify
SIV
SIV is an inactivated Simian Immunodeficiency Virus vaccine candidate designed to elicit immune responses against SIV infection.
SIV is an inactivated Simian Immunodeficiency Virus vaccine candidate designed to elicit immune responses against SIV infection. Used for Research tool for studying SIV infection in non-human primates.
At a glance
| Generic name | SIV |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Virology/Research |
| Phase | FDA-approved |
Mechanism of action
SIV vaccines are developed as research tools and potential preventive agents against Simian Immunodeficiency Virus, which is used in non-human primate models to study HIV pathogenesis and vaccine development. The inactivated formulation aims to stimulate both cellular and humoral immune responses without causing active infection. This vaccine platform has primarily been used in preclinical and research settings rather than for human therapeutic use.
Approved indications
- Research tool for studying SIV infection in non-human primates
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age (PHASE3)
- Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection (PHASE4)
- Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia (PHASE3)
- A Randomized Controlled Trial Evaluating an Online Intervention in Increasing Seasonal Influenza Vaccination Among Community Dwelling People Aged ≥65 Years (NA)
- The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine (PHASE4)
- GCF Levels of IL-1Beta, MIP-1 Alfa and G-CSF in Gingivitis and Stage I-II-III-IV Periodontitis Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIV CI brief — competitive landscape report
- SIV updates RSS · CI watch RSS
- Zhejiang Provincial Center for Disease Control and Prevention portfolio CI